Literature DB >> 7977303

Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells.

P L Zinzani1, P Tosi, G Visani, G Martinelli, P Farabegoli, M Buzzi, E Ottaviani, M Salvucci, M Bendandi, A Zaccaria.   

Abstract

The cytotoxic effects and the induction of programmed cell death (apoptosis) by Fludarabine (FLU), 2-chlorodeoxyadenosine (2-CdA), and deoxycoformycin (DCF) with/without alpha-interferon (alpha-IFN) were evaluated in vitro against freshly isolated B-chronic lymphocytic leukemia (B-CLL) cells. Cytotoxicity was evaluated according to the soluble tetrazolium/formazan assay. Regarding the cytotoxicity, FLU, 2-CdA, and DCF showed a mean antitumor activity of 45% +/- 3.39 (mean +/- S.D.), 55% +/- 4.72, and 20% +/- 3.16, respectively. alpha-IFN alone showed a mean cytotoxic activity of 10% +/- 2.72. The cytotoxicity of these purine analogues in combination with alpha-IFN was 52% +/- 2.97, 75% +/- 3.41, and 26% +/- 7.09, respectively. We observed a statistically significant increase of cytotoxicity compared to controls in FLU alone (P < 0.05), 2-CdA (P < 0.05), and their combination with alpha-IFN (P < 0.05). Apoptosis was evaluated by electrophoresis gel of DNA oligonucleosomal fragments and by a cytofluorimetric method. Only FLU and 2-CdA activated the apoptosis and DCF showed a minor apoptotic pathway amount. These apoptosis data were confirmed by both gel electrophoresis of DNA and by propidium iodide cytofluorimetric method. FLU and 2-CdA show activity in B-CLL cells by direct cytotoxic action and the induction of cell death by apoptosis; in the future, it would be interesting to utilize these in vitro assays in monitoring chemosensitivity and predicting response for the clinical use.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7977303     DOI: 10.1002/ajh.2830470410

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  3 in total

Review 1.  Apoptosis: molecular mechanisms and implications for cancer chemotherapy.

Authors:  H J Guchelaar; A Vermes; I Vermes; C Haanen
Journal:  Pharm World Sci       Date:  1997-06

Review 2.  Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors:  J C Adkins; D H Peters; A Markham
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

3.  Down-regulation of telomerase activity in malignant lymphomas by radiation and chemotherapeutic agents.

Authors:  Z Lin; S Lim; M A Viani; M Sapp; M S Lim
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.